Tower Research Capital LLC (Trc) Verve Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 13,397 shares of VERV stock, worth $83,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,397
Previous 26,287
49.04%
Holding current value
$83,061
Previous $127,000
40.94%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VERV
# of Institutions
180Shares Held
76.4MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$76.6 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$42.8 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$24.8 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$24.8 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $372M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...